Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL11689582 | 0.88 | CA1 (0.47) | CA1CA2CA9CA4CA6 | |
| Pyridine SCHEMBL11570751 | 0.80 | NAPRT (0.60) | CA1CA2CA9CA4CA6 | |
| Pyrimidine SCHEMBL29040951 | 0.80 | NAPRT (0.42) | CA5ACA5BNAPRTTSHRTDP1 | |
| Pyrimidine SCHEMBL29127643 | 0.80 | — | — | |
| Pyrimidine SCHEMBL9322876 | 0.80 | NAPRT (0.42) | CA5ACA5BNAPRTTSHRTDP1 | |
| Pyrimidine SCHEMBL6216525 | 0.80 | KDM4E (0.40) | NAPRTTSHRTDP1CYP2A6 | |
| Pyrimidine SCHEMBL6218703 | 0.80 | TDP1 (0.35) | NAPRTTSHRTDP1CYP2A6 | |
| Pyrimidine SCHEMBL389598 | 0.80 | NAPRT (0.42) | CA5ACA5BNAPRTTSHRTDP1 | |
| Pyrimidine SCHEMBL21056190 | 0.80 | NAPRT (0.42) | CA5ACA5BNAPRTTSHRTDP1 | |
| Pyrimidine SCHEMBL6837713 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023111797-A1 | PYRIMIDINE SULFAMIDE DERIVATIVES AND PROCESS FOR MANUFACTURING THEM | JANSSEN BIOTECH, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111797-A1 | PYRIMIDINE SULFAMIDE DERIVATIVES AND PROCESS FOR MANUFACTURING THEM | JANSSEN BIOTECH, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11648249-B2 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | ACTELION PHARMACEUTICALS LTD (CH) | 2023-05-16 | — | — | US | disclosed |
| EP-3719013-B1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | WUXI BIOCITY BIOPHARMACEUTICS CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| EP-3719013-B1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | WUXI BIOCITY BIOPHARMACEUTICS CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| EP-3214082-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-11-10 | — | — | EP | disclosed |
| EP-3214082-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-11-10 | — | — | EP | disclosed |
| EP-3719013-A4 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-04-21 | — | — | EP | disclosed |
| CN-1711248-A | pyrimidine-sulfonamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-21 | — | — | CN | disclosed |
| CN-1711248-A | pyrimidine-sulfonamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-21 | — | — | CN | disclosed |
| CN-1668189-A | Liquid adjuvants | BAYER CROPSCIENCE GMBH (DE) | 2005-09-14 | — | — | CN | disclosed |
| CN-1668190-A | Solid adjuvants | BAYER CROPSCIENCE GMBH (DE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1569914-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | Actelion Pharmaceuticals Ltd. (CH) | 2005-09-07 | — | — | EP | disclosed |
| CN-1587263-A | Novel pyrimidyl sulfamide compounds with anti-tumor activity and their salts | XINXING MEDICINE CO LTD SHANGH (CN) | 2005-03-02 | — | — | CN | disclosed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | TBXA2R, P2RY11, TPMT | CA1 4518/4885CA2 3961/4885CA9 4238/4885 |
| US-11648249-B2 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | DPYD, TYMS, TYMP | CA1 3536/4885CA2 2735/4885CA9 2068/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | CA1 4222/4885CA2 1613/4885CA9 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.